Cero Therapeutics director granted 690,900 stock options at $0.055

Cero Therapeutics Holdings, Inc. director Michael Byrnes received a grant of stock options on January 7, 2026.

Rhea-AI Filing Summary

Cero Therapeutics Holdings, Inc. director Michael Byrnes received a grant of stock options on January 7, 2026. The award covers 690,900 stock options, each giving the right to buy one share of common stock at an exercise price of $0.055 per share. These options are held as direct ownership and are exercisable starting January 7, 2026, with an expiration date of January 6, 2036. The filing reports this derivative award and the resulting beneficial ownership of 690,900 derivative securities after the transaction.

Insider Trade Summary

Grant/Award: 690,900 shares

Grant/Award 1 txn

Insider Byrnes Michael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	690,900	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 690,900 contracts (Direct)

FAQ

What insider transaction did Cero Therapeutics (CERO) report for Michael Byrnes?

Cero Therapeutics reported that director Michael Byrnes received a grant of 690,900 stock options on January 7, 2026.

What is the exercise price of Michael Byrnes’ stock options in Cero Therapeutics (CERO)?

The stock options granted to Michael Byrnes have an exercise price of $0.055 per share of common stock.

When do Michael Byrnes’ Cero Therapeutics stock options expire?

The stock options granted to Michael Byrnes become exercisable on January 7, 2026 and expire on January 6, 2036.

How many Cero Therapeutics derivative securities does Michael Byrnes own after this transaction?

After the reported transaction, Michael Byrnes beneficially owns 690,900 derivative securities in the form of stock options.

Is Michael Byrnes’ ownership in Cero Therapeutics reported as direct or indirect?

The filing shows Michael Byrnes’ stock options as direct (D) ownership with no indicated indirect ownership entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Byrnes Michael

(Last) (First) (Middle)

CERO THERAPEUTICS HOLDINGS, INC.

201 HASKINS WAY, SUITE 230

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CERO THERAPEUTICS HOLDINGS, INC. [ CERO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.055	01/07/2026		A		690,900		01/07/2026	01/06/2036	Common Stock	690,900	$0.00	690,900	D

Explanation of Responses:

	/s/ Andrew Kucharchuk, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.